Of those patients commenced on LDTA; 10 (83%) entered clinical remission. 2 (17%) failed due to lack of clinical response and commenced MTX. 10 remain in a sustained clinical remission at a mean length of follow up of 16.2 months (range: 4–23).

Of the 10 patients commenced on MTX; 7 (70%) failed due to lack of clinical response and 1 (10%) due to side-effects (Pneumonitis). Of those patients that failed; 4 (40%) underwent colectomy, 2 (20%) received arsenic suppositories and entered a sustained clinical remission. 2 (20%) were reclassified to Crohn’s disease, were treated with biologic therapy and entered a sustained clinical remission. Mean length of follow up in this group was 17.6 months (range: 2–30).

**Conclusion**

Thioureas remain the mainstay of treatment for patients with UC. A significant number of patients fail this conventional treatment and represent a clinical challenge. Novel treatments such as LDTA can be effective in a significant proportion of this group. Data for the efficacy of MTX remains less effective and topical arsenic is useful and can be helpful.

**Disclosure of Interest**

T. Hollingworth: None Declared, H. JOHNSTON Conflict with: SPONSORSHIP FROM FALK, ABBOTT & WARNER CHILCOTT TO ATTEND MEETINGS, R. BASUROY: None Declared, S. MCLAUGHLIN Conflict with: SPONSORSHIP FROM FALK TO ATTEND MEETINGS, S. WEAVER Consultant for: MSD ADVISORY BOARD, Conflict with: SPONSORSHIP FROM FALK, ABBOT, MSD & FERRING TO ATTEND MEETINGS

**PTH-116 MICROSCOPIC COLITIS IN TAYSIDE – FURTHER OBSERVATIONS ON CLINICAL FEATURES AND OUTCOME**

doi:10.1136/gutjnl-2013-304907.603

1,*T Heron, 1C Mowat, 1M Groome, 2S Walsh, 1S Siddhi, 1A Meritsi.
1Gastroenterology; 2Pathology, NHS Tayside, Dundee, UK

**Introduction**
The aetiology of microscopic colitis remains unknown. We have previously reported our experience of microscopic colitis diagnosed in our region between 1999 – 2004(1). Although data continue to emerge, the natural history of microscopic colitis remains unclear. Furthermore, there are reports of macroscopic changes in the mucosa at endoscopy.

**Methods**
Cases from 2004–2011 were identified from pathology records. Case notes were retrospectively reviewed and data extracted including subtype of microscopic colitis and clinical details where possible.

**Results**
82 case notes were obtained and reviewed. 8 cases did not have a clear diagnosis and were excluded. Of the remaining 74 cases, 56 were collagenous colitis, 18 lymphocytic colitis. 17 patients had macroscopic abnormalities (excluding diverticulosis) at endoscopy; 16 of these in the collagenous colitis group, representing 28% of this subgroup. The mean age was 46.1 (range 33–87), female: male ratio of 4.3:1. 18 reported an autoimmune condition including 2 coeliac disease and 7 hypothyroidism. 30(40%) were on a proton pump inhibitor at the time of diagnosis and 15(24%) were on non-steroidal anti-inflammatoryatories. Follow up data was available for 66 patients. Of these 47(71%) reported complete resolution of symptoms and 15(22%) partial resolution. 5(7%) did not respond in the follow up period. Therapeutic strategies included either alone or a combination of stopping/switching PPI, loperamide, mesalazine and steroids. 24/47(65%) of complete responders required simple intervention (PPI withdrawal, switch in brand of PPI, loperamide or even spontaneous resolution) whereas 10/47(21%) required steroids. 7/15(47%) partial responders received steroids.

**Conclusion**

Since microscopic colitis was last studied in our region, the female predominance has increased, the mean age has dropped by almost 20yrs, and the ratio of collagenous : lymphocytic colitis has increased from 2:1 to 3:1. This could represent a change in the number of younger people investigated or missing data in our cohort. A significant number of patients with a diagnosis of collagenous colitis had endoscopic abnormalities in comparison to the lymphocytic colitis group, which does raise the question of the nomenclature. The majority of patients have complete resolution of symptoms with simple intervention.

**Disclosure of Interest**

None Declared.

**REFERENCE**
1. Microscopic Colitis in Tayside: Clinical features, associations and behaviour. Mowat C, Heron T, Walsh S. Gastroenterology 2005: 128 (4); A331

**PTH-117 PREDICTING THE NEED FOR DOSE ESCALATION IN PATIENTS WITH CROHN’S DISEASE TREATED WITH ADALIMUMAB**

doi:10.1136/gutjnl-2013-304907.604

1,*V C Kariyawasam, 1M G Ward, 2V Collings, 1K Patel, 1R Goel, 1P A Blaker, 1S Anderson, 1J D Sanderson, 1P M Irving. 1Gastroenterology; 2Pharmacy, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

**Introduction**

A significant number of patients with a diagnosis of collagenous colitis had endoscopic abnormalities in comparison to the lymphocytic colitis group, which does raise the question of the nomenclature. The majority of patients have complete resolution of symptoms with simple intervention.
Introduction Adalimumab (ADA) is effective for the induction and maintenance of remission in Crohn’s disease (CD) patients. Although the approved maintenance regimen is 40 mg subcutaneously every 14 days, some patients require dose-escalation (DE). Methods Aim of the study was to describe a large, well-characterised cohort of ADA treated CD patients in a tertiary referral centre and to identify factors predicting the need for DE. A prospectively maintained database of CD patients treated with ADA at the Guy’s and St Thomas’ IBD Center between 2007–2012 was interrogated. Clinical and phenotypic details and exposure to therapy were analysed. Survival and regression analyses were performed.

Results 112 CD (50% Male) patients commenced ADA. Three patients had coexisting Oro-Facial Granulomatosis. Mean age at diagnosis was 22 (SD; 9) years. Disease location was ileo-colonic (68.8%) in the majority. Upper gastrointestinal (UGI) involvement was found in 17.9%, peri-anal disease in 29.5% and extra-intestinal manifestations in 14.3%.

Median duration of disease prior to ADA initiation was 11 years (IQR, 5–18). Previous infliximab (IFX), ADA and exposure to both were found in 59, 3 and 7 patients respectively. Of the 66 patients exposed to IFX 29 (43.9%) had primary or secondary loss of response. A total of 82 (71.3%) were on concomitant immunomodulators (CIM) - azathioprine, mercaptopurine, thioguanine or methotrexate at the time of initiation of ADA.

103 (89.3) patients responded to ADA induction. 4 patients were primary non-responders, 5 withdrew due to adverse effects. All 4 primary non-responders and 3/5 who withdrew were previously exposed to IFX.

DE was required in 40 (38.8%) of the responders during the follow-up period at a median 26 months (95% confidence interval (CI); 19.6–32.4). Cumulative probability of requiring DE at 24 months was 52% (CI; 42–62). CIM at initiation of ADA (Odds ratio (OR): 0.21, CI: 0.09–0.47, p = 0.002) and UGI involvement (OR: 3.43, CI: 1.02–11.42, p = 0.046) were independently associated with need for DE in multivariate analysis.

CIM at commencement of ADA was associated with increased time to DE (Hazard ratio: 0.34, CI: 0.18–0.64, p = 0.001). 24/38 (63.25%) patients responded to DE, 2 patients had incomplete follow-up data.

Conclusion 38.8% of CD patients commencing ADA in this well defined cohort required DE due to loss of response, of which 63% were recaptured. CIM at initiation predicted a more durable response to standard dosing. UGI involvement and previous exposure to IFX were independently associated with increased risk of requiring DE.

Disclosure of Interest None Declared.

Conclusion Our results show that patients reporting more effective results after the second sacchet was more effective than the first had poorer bowel prep at colonoscopy (p = 0.05). Patients who reported their usual bowel habit as hard, and those with diabetes, had a tendency towards having their bowels open most after the second sacchet, but neither relationship was statistically significant (p = 0.15 & 0.18 respectively).

No correlations were found between patient gender, age or drinking habits and perceived quality of prep or efficacy of each sacchet.

Disclosure of Interest None Declared.

REFERENCE

NURSES AND ENDOCOSPISTS ARE EQUALLY GOOD AT GAUGING PATIENT DISTRESS DURING ENDOCOSPY

NURSES AND ENDOCOSPISTS ARE EQUALLY GOOD AT GAUGING PATIENT DISTRESS DURING ENDOCOSPY

Introduction Endoscopic procedures have the potential to be uncomfortable and distressing. Previous studies have suggested nurses are better than endoscopists at gauging a patient’s pain during endoscopy, possibly reflecting the endoscopists focus on the procedure as opposed to the nurse whose focus remains on the patient. Currently, there is a paucity of work evaluating distress another important marker of endoscopic tolerability. This study evaluates endoscopists’ and nurses’ ability to gauge patient’s distress during gastrointestinal endoscopic procedures.

Methods Consecutive patients attending for clinically indicated gastrointestinal endoscopy were prospectively recruited from a tertiary referral centre between September 2011 and June 2012. Following informed consent being obtained patients were asked to record distress post endoscopy using a validated numeric rating scale (NRS), with scores recorded between 0 (no distress) and 10 (worst distress imaginable). Endoscopists undertaking the procedure and their assisting nurses were then asked to give their estimates of patient’s distress using the same NRS, with recordings undertaken separately so as not to influence potential outcomes. Data was analysed using SPSS version 20, with a correlation coefficient used to determine levels of agreement in distress scores.

NURSES AND ENDOCOSPISTS ARE EQUALLY GOOD AT GAUGING PATIENT DISTRESS DURING ENDOCOSPY

NURSES AND ENDOCOSPISTS ARE EQUALLY GOOD AT GAUGING PATIENT DISTRESS DURING ENDOCOSPY